

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
2 December 2004 (02.12.2004)

PCT

(10) International Publication Number  
**WO 2004/103369 A1**

(51) International Patent Classification<sup>7</sup>: A61K 31/4406, 33/24, 31/282, 31/70, 31/4745, 31/513, 31/7068, 31/337, 31/555, 31/704, A61P 35/00, A61K 31/475

(74) Agents: AOKI, Atsushi et al.; A. Aoki, Ishida & Associates, Toranomon 37 Mori Bldg., 5-1, Toranomon 3-chome, Minato-ku, Tokyo 1058423 (JP).

(21) International Application Number:  
PCT/JP2004/007562

(22) International Filing Date: 26 May 2004 (26.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(30) Priority Data:  
2003-148073 26 May 2003 (26.05.2003) JP

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): SCHERRING AKTIENGESELLSCHAFT [DE/DE]; Muellerstrasse 178, 13353 Berlin (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NAKANISHI, Osamu [JP/JP]; 1656-13, Tokecho, Midori-ku, Chiba-shi, Chiba 2670061 (JP). SUGAWARA, Tatsuo [JP/JP]; 18-1, Oyuminoariyoshi, Midori-ku, Chiba-shi, Chiba 2660034 (JP). MIGITA, Hideyuki [JP/US]; 207 Shoreline Court, Richmond, CA 94804 (US). MATSUBA, Yasuhiro [JP/JP]; 9-4-802, Nakayacho, Nishinomiya-shi, Hyogo 6620868 (JP).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/103369 A1

(54) Title: PHARMACEUTICAL COMPOSITION CONTAINING HISTONE DEACETYLASE INHIBITOR

(57) Abstract: An anticancer drug having a synergistic effect by combined use of a histone acetylase derivative such as N-(2-aminophenyl)-4-[N-(pyridin-3-ylmethoxycarbonyl) aminomethyl]benzamide (MS-275) and another anticancer active substance.

- 1 -

DESCRIPTION

PHARMACEUTICAL COMPOSITION CONTAINING HISTONE DEACETYLASE  
INHIBITOR

5

TECHNICAL FIELD

The present invention relates to a pharmaceutical composition or drug combination for treatment of cancer comprising a histone deacetylase inhibitor and another anticancer active substance.

10

BACKGROUND ART

At the present time, cancer is the first leading cause of death. Up until now, many researchs on cancer have been conducted and tremendous money and time have been spended on these researchs. However, despite research in methods of treatment spanning diverse fields such as surgery, radiotherapy, and thermotherapy, cancer has not been overcome. Among these, chemotherapy is a major sector and many anticancer drugs have been researched. For example, as chemotherapy drugs for cancer, cisplatin, etoposide, 5-fluorouracil, gemcitabine, paclitaxel, docetaxel, carboplatin, oxaliplatin, doxorubicin, vinblastin, etc. have been used.

15

Japanese Unexamined Patent Publication (Kokai) No. 10-152462 discloses a benzamide derivative. The following fact is disclosed; said benzamide derivative has a differentiation inducing action, is useful as a pharmaceutical for the treatment or alleviation of malignant tumors, autoimmune diseases, skin diseases, and parasitic infection, is particularly effective as an anticancer drug, and is effective against hematopoietic cancers and solid cancers.

20

Patent Document 1

25

Japanese Unexamined Patent Publication (Kokai) No. 10-152462


DISCLOSURE OF THE INVENTION

However, anticancer drugs have limitation at a dosage of a single drug due to their strong toxicity to normal cells. Except for some cancers, treatment by administration of a single drug is not enough to achieve 5 a sufficient efficacy.

The present invention was made to reduce the toxicity posing a problem in current chemotherapy and achieve a high treatment effect.

Accordingly, the present invention provides a 10 pharmaceutical composition or combination as active ingredients comprising:

(a) at least one of the benzamide derivatives represented by formula (1):




20 wherein A is an optionally substituted phenyl group or an optionally substituted heterocyclic group wherein the substituent(s) for the phenyl group or the heterocyclic group is (are) 1 to 4 substituents selected from the group consisting of a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, an alkyl group having 1 to 4 carbons, an alkoxy group having 1 to 4 carbons, an aminoalkyl group having 1 to 4 carbons, an alkylamino group having 1 to 4 carbons, an acyl group having 1 to 4 carbons, an acylamino group having 1 to 4 carbons, an alkylthio group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a perfluoroalkyloxy group having 1 to 4 carbons, a carboxyl group, an alkoxy carbonyl group having 1 to 4 carbons, a phenyl group and a heterocyclic group;

25

30

35 X is a bond or a moiety having a structure selected from those illustrated in formula (2):

- 3 -



wherein e is an integer of 1 to 4; g and m are independently an integer of 0 to 4; R4 is a hydrogen atom or an optionally substituted alkyl group having 1 to 4 carbons, or the acyl group represented by formula (3)




wherein R6 is an optionally substituted alkyl group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a phenyl group or a heterocyclic group; R5 is a hydrogen atom or an optionally substituted alkyl group having 1 to 4 carbons;

n is an integer of 0 to 4, provided that when X is a bond, n is not zero;

Q is a moiety having a structure selected from those illustrated in formula (4)

- 4 -



wherein R7 and R8 are independently a hydrogen atom or an optionally substituted alkyl group having 1 to 4 carbons;

R1 and R2 are independently a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, an alkyl group having 1 to 4 carbons, an alkoxy group having 1 to 4 carbons, an aminoalkyl group having 1 to 4 carbons, an alkylamino group having 1 to 4 carbons, an acyl group having 1 to 4 carbons, an acylamino group having 1 to 4 carbons, an alkylthio group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a perfluoroalkyloxy group having 1 to 4 carbons, a carboxyl group or an alkoxycarbonyl group having 1 to 4 carbons;

R3 is a hydroxyl group or amino group or a pharmaceutically acceptable salt thereof as HDAC inhibiting substance, and

30 (b) at least one substance as another anti-cancer active substance selected from a group consisting of cisplatin, etoposide, camptothecin, 5-fluorouracil, gemcitabine, paclitaxel, docetaxel, carboplatin, oxaliplatin, doxorubicin and vinblastin.

The present invention further provides a cancer treatment kit comprising a pharmaceutical combination, which comprises:

(i) at least one of said ingredients (a) which is a

histone deacetylase inhibiting substance,

(ii) at least one of said ingredients (b) which is another anti-cancer active substance, and





5 (iii) an instruction for administration schedule for simultaneous or sequential administration according to a kind of cancer (for sequential administration to a patient at periodic intervals).

The "pharmaceutical combination" in the present invention means a combination of an ingredient (a) which 10 is a histone deacetylase inhibiting substance and an ingredient (b) which is another anti-cancer active substance, wherein the ingredient (a) and the ingredient (b) are administered simultaneously or at different times (or sequentially).


15 The present invention includes a method of treatment of cancer comprising administering said ingredient (a) and said ingredient (b) to patients simultaneously or at different times (or sequentially). In this situation, an administration sequence of said ingredient (a) and said 20 ingredient (b) is appropriately selected according to a kind of cancer and kinds of said ingredient (a) and said ingredient (b). Further, the present invention also includes use of said ingredient (a) and said ingredient (b) for producing a pharmaceutical composition or drug 25 combination of the present invention for treating cancer and use of said ingredient (a) and said ingredient (b) for producing the kit of the present invention.

The benzamide derivative which is a histone deacetylase inhibiting substance or pharmaceutically acceptable salts thereof is preferably selected from represented by the following formulas (5) to (8):

- 6 -



More preferably, the benzamide derivative is represented by the following formula (5) or pharmaceutically acceptable salt thereof:



In the pharmaceutical combination or composition in the present invention, said ingredient (b) which is another anti-cancer active substance is preferably cisplatin, more preferably the combination or composition which is for treatment of colon cancer, non-small cell lung cancer, ovarian cancer or pancreatic cancer.

Further, in the pharmaceutical combination or composition in the present invention, said ingredient (b) which is another anti-cancer active substance is preferably etoposide, more preferably the combination or composition which is for treatment of ovarian cancer.

Further, in the pharmaceutical combination or composition in the present invention, said ingredient (b) which is another anti-cancer active substance is preferably camptothecin, more preferably the combination or composition which is for treatment of colon cancer, non-small cell lung cancer, ovarian cancer or pancreatic cancer.

Further, in the pharmaceutical combination or composition in the present invention, said ingredient (b) which is another anti-cancer active substance is preferably 5-fluorouracil, more preferably the combination or composition which is for treatment of breast cancer or colon cancer.

Further, in the pharmaceutical combination or composition in the present invention, said ingredient (b) which is another anti-cancer active substance is preferably gemcitabine, more preferably the combination or composition which is for treatment of non-small cell lung cancer, colon cancer or ovarian cancer.

Further, in the pharmaceutical combination or composition in the present invention, said ingredient (b) which is another anti-cancer active substance is preferably paclitaxel, more preferably the combination or composition which is for treatment of breast cancer, prostate cancer or ovarian cancer.

Further, in the pharmaceutical combination or

composition in the present invention, said ingredient (b) which is another anti-cancer active substance is preferably docetaxel, more preferably the combination or composition which is for treatment of non-small cell lung cancer, ovarian cancer, pancreatic cancer or prostate cancer.

Further, in the pharmaceutical combination or composition in the present invention, said ingredient (b) which is another anti-cancer active substance is preferably carboplatin, more preferably the combination or composition which is for treatment of non-small cell lung cancer, ovarian cancer or pancreatic cancer.

Further, in the pharmaceutical combination or composition in the present invention, said ingredient (b) which is another anti-cancer active substance is preferably oxaliplatin, more preferably the combination or composition which is for treatment of colon cancer or ovarian cancer.

Further, in the pharmaceutical combination or composition in the present invention, said ingredient (b) which is another anti-cancer active substance is preferably doxorubicin, more preferably the combination or composition which is for treatment of ovarian cancer.

Further, in the pharmaceutical combination or composition in the present invention, said ingredient (b) which is another anti-cancer active substance is preferably vinblastin, more preferably the combination or composition which is for treatment of non-small cell lung cancer.

Further, the pharmaceutical combination in the present invention is preferable, of which said ingredient (a) which is histone deacetylase inhibiting substance and said ingredient (b) which is another anti-cancer active substance are sequentially administered to patients.

Of the pharmaceutical combination, said ingredient (b) which is another anti-cancer active substance is preferably paclitaxel. As the administration sequence

thereof, it is preferable to administer paclitaxel and then said ingredient (a) which is a histone deacetylase inhibiting substance. The pharmaceutical combination for treatment of breast cancer or ovarian cancer is more preferable.

Further, of the pharmaceutical combination, said ingredient (b) which is another anti-cancer active substance is preferably cisplatin. As the administration sequence thereof, it is preferable to administer said ingredient (a) which is a histone deacetylase inhibiting substance, and then cisplatin. The pharmaceutical combination for treatment of non-small cell lung cancer is more preferable. Or, the administration sequence thereof is preferably cisplatin, and then said ingredient (a) which is a histone deacetylase inhibiting substance. The pharmaceutical combination for treatment of colon cancer, non-small cell lung cancer, ovarian cancer or pancreatic cancer is more preferable.

Further, of the pharmaceutical combination, said ingredient (b) which is another anti-cancer active substance is preferably gemcitabine. As the administration sequence thereof, it is preferable to administer said ingredient (a) which is a histone deacetylase inhibiting substance, and then gemcitabine. The pharmaceutical combination for treatment of non-small cell lung cancer is more preferable. Or, the administration sequence thereof is preferably gemcitabine, and then said ingredient (a) which is a histone deacetylase inhibiting substance. The pharmaceutical combination for treatment of colon cancer, non-small cell lung cancer, ovarian cancer or pancreatic cancer is more preferable.

Further, of the pharmaceutical combination, said ingredient (b) which is another anti-cancer active substance is preferably docetaxel. As the administration sequence thereof, it is preferable to administer docetaxel, and then said ingredient (a) which is a

histone deacetylase inhibiting substance. The pharmaceutical combination for treatment of non-small cell lung cancer, ovarian cancer, pancreatic cancer or prostate cancer is more preferable.

5       Further, of the pharmaceutical combination, said ingredient (b) which is another anti-cancer active substance is preferably carboplatin. As the administration sequence thereof, it is preferable to administer carboplatin, and then said ingredient (a) 10 which is a histone deacetylase inhibiting substance. The pharmaceutical combination for treatment of non-small cell lung cancer, ovarian cancer, pancreatic cancer or prostate cancer is more preferable.

15      Further, of the pharmaceutical combination, said ingredient (b) which is another anti-cancer active substance is preferably oxaliplatin. As the administration sequence thereof, it is preferable to administer oxaliplatin, and then said ingredient (a) 20 which is a histone deacetylase inhibiting substance. The pharmaceutical combination for treatment of colon cancer or ovarian cancer is more preferable.

25      Further, of the pharmaceutical combination, said ingredient (b) which is another anti-cancer active substance is preferably doxorubicin. As the administration sequence thereof, it is preferable to administer doxorubicin, and then said ingredient (a) which is a histone deacetylase inhibiting substance. The pharmaceutical combination for treatment of ovarian 30 cancer is more preferable.

30      Further, of the pharmaceutical combination, said ingredient (b) which is another anti-cancer active substance is preferably vinblastin. As the administration sequence thereof, it is preferable to administer vinblastin, and then said ingredient (a) which is a 35 histone deacetylase inhibiting substance. The pharmaceutical combination for treatment of non-small cell lung cancer is more preferable.

Further, of the pharmaceutical combination, said ingredient (b) which is another anti-cancer active substance is preferably 5-fluorouracil. As the administration sequence thereof, it is preferable to 5 administer 5-fluorouracil, and then said ingredient (a) which is a histone deacetylase inhibiting substance. The pharmaceutical combination for treatment of colon cancer is more preferable.

In the pharmaceutical composition of the present 10 invention, said ingredient (a) and said ingredient (b) may be made into the pharmaceutical composition using compound per se which are these active ingredients, may be made into the pharmaceutical composition using a preparation containing said ingredient (a) as an active 15 ingredient and a preparation containing said ingredient (b) as an active ingredient, or may be made into the pharmaceutical composition using the compound per se which is either of said ingredient (a) or said ingredient (b) and a preparation of the other prepared in advance. 20 And, in the pharmaceutical combination of the present invention, usually separately prepared preparations, that is, a preparation containing said ingredient (a) as an active ingredient and a preparation containing said 25 ingredient (b) as an active ingredient, are administered simultaneously or at a different time (or consecutively).

#### BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 is a graph showing the principle of judgment of the existence of a synergistic action.

#### BEST MODE FOR CARRYING OUT THE INVENTION

30 The present invention relates to a pharmaceutical composition or combination comprising a benzamide derivative represented by formula (1) which is a histone deacetylase inhibiting substance and another anticancer active substance.

35 As used herein, "1 to 4 carbons" means a carbon number per a single substituent; for example, for dialkyl substitution it means 2 to 8 carbons.

A heterocycle in the compound represented by formula (1) is a monocyclic heterocycle having 5 or 6 members containing 1 to 4 nitrogen, oxygen or sulfur atoms or a bicyclic-fused heterocycle. The monocyclic heterocycle includes pyridine, pyrazine, pyrimidine, pyridazine, thiophene, furan, pyrrole, pyrazole, isoxazole, isothiazole, imidazole, oxazole, thiazole, piperidine, piperazine, pyrrolidine, quinuclidine, tetrahydrofuran, morpholine, thiomorpholine and the like. The bicyclic fused heterocycle includes quinoline; isoquinoline; naphthyridine; fused pyridines such as fuopyridine, thienopyridine, pyrrolopyridine, oxazolopyridine, imidazolopyridine and thiazolopyridine; benzofuran; benzothiophene; benzimidazole and the like. A halogen may be fluorine, chlorine, bromine or iodine. An alkyl having 1 to 4 carbons includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.

An alkoxy having 1 to 4 carbons includes methoxy, ethoxy, n-propoxy, isopropoxy, allyloxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like.

An aminoalkyl having 1 to 4 carbons includes aminomethyl, 1-aminoethyl, 2-aminopropyl and the like. An alkylamino having 1 to 4 carbons includes N-methylamino, N,N-dimethylamino, N,N-diethylamino, N-methyl-N-ethylamino, N,N-diisopropylamino and the like. An acyl having 1 to 4 carbons includes acetyl, propanoyl, butanoyl and like. An acylamino having 1 to 4 carbons includes acetylamino, propanoylamino, butanoylamino and the like. An alkylthio having 1 to 4 carbons includes methylthio, ethylthio, propylthio and the like. A perfluoroalkyl having 1 to 4 carbons includes trifluoromethyl, pentafluoroethyl and the like. A perfluoroalkyloxy having 1 to 4 carbons includes trifluoromethoxy, pentafluoroethoxy and the like. An alkoxycarbonyl having 1 to 4 carbons includes methoxycarbonyl and ethoxycarbonyl. An optionally substituted alkyl having 1 to 4 carbons includes methyl,

ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl and these having 1 to 4 substituents selected from the group consisting of a halogen, hydroxyl, amino, nitro, cyano, phenyl and a heterocycle.

5 A pharmaceutically acceptable salt of ingredient (a) as histone deacetylase inhibiting substance of this invention includes salts with an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid; and with an organic acid such as acetic acid, lactic acid, tartaric acid, malic acid, succinic acid, fumaric acid, maleic acid, citric acid, benzoic acid, trifluoroacetic acid, p-toluenesulfonic acid and methanesulfonic acid.

15 The ingredient (a) which is a histone deacetylase inhibiting substance of this invention may be produced in accordance with the process of Japanese unexamined patent publication (Kokai) No. 10-152462. And, the ingredient (b) which is another anti-cancer active substance is commercially available or can be produced by known methods.

20 The pharmaceutical composition or combination of this invention is useful for cancer treatment. The composition itself may be used in the form of a general pharmaceutical formulation. And of the combination the ingredients (a) and (b) may be used in the form of a general pharmaceutical formulation.

25 The pharmaceutical composition comprising the active ingredient (a) and (b) is prepared with a generally used diluent or excipient such as filler, extender, binder, moisturizing agent, disintegrator, surfactant and lubricant. And the pharmaceutical combination is prepared by independent active ingredients, with a generally used diluent or excipient such as filler, extender, binder, moisturizing agent, disintegrator, surfactant and lubricant. The pharmaceutical formulation may have a variety of dosage forms such as tablet, pill, powder, solution, suspension, emulsion, granule, capsule,

injection (e.g., solution, suspension) and suppository.

For preparing tablets, a variety of carriers well-known in the art may be used. Such a carrier includes excipients such as lactose, glucose, starch, calcium carbonate, kaoline, crystalline cellulose and silicic acid; binders such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose and polyvinyl pyrrolidone; disintegrators such as dried starch, sodium alginate, powdered agar, calcium carmelose, starch and lactose; disintegration retarders such as sucrose, cocoa butter and hydrogenated oil; absorption promoters such as quaternary ammonium base and sodium lauryl sulfate; moisturizing agents such as glycerin and starch; adsorbents such as starch, lactose, kaoline, bentonite, colloidal silicic acid; and glidants such as talc, stearates and polyethylene glycol. The tablet may be, if necessary, one coated with a common coating; for example, sugar-coated tablet, gelatin-coated tablet, enteric coated tablet, film-coated tablet, double-layer tablet and multilayer tablet.

In forming pills, a variety of carriers well-known in the art may be used. Such a carrier includes excipients such as crystalline cellulose, lactose, starch, hydrogenated vegetable oil, kaoline and talc; binders such as powdered acacia, powdered tragacanth gum and gelatin; disintegrators such as calcium carmelose and agar.

Capsule may be prepared by blending an active ingredient with a variety of the above carriers as usual and filling the resulting blend into, for example, a hard or soft gelatin capsule or the like.

For preparing injection, solution, emulsion and suspension are sterilized and preferably isotonic with blood. It may be prepared using diluents commonly used in the art; for example, water, ethanol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxyisostearyl

alcohol and polyoxyethylene sorbitan fatty acid esters. The pharmaceutical preparation may contain sodium chloride necessary to prepare an isotonic solution, glucose or glycerin, as well as usual solubilizers, 5 buffers and soothing agents.

Suppository may be formed using a variety of well-known carriers; for example, semi-synthetic glyceride, cocoa butter, higher alcohols, higher alcohol esters and polyethylene glycol.

10 Furthermore, the pharmaceutical formulation may contain coloring agents, preservatives, perfumes, flavors, sweeteners and/or other drugs.

The volume ratio of the active ingredients (b) to 15 (a) to be included in the pharmaceutical composition of the present invention is not limited and is appropriately selected from a broad range of the volume ratios. In the case of cisplatin, the molar ratio is 0.001 to 10000, preferably 0.01 to 1000, to 1 of the benzamide derivative (said ingredient (a)). In the case of etoposide, the 20 molar ratio is 0.001 to 10000, preferably 0.01 to 1000, to 1 of the benzamide derivative.

In the case of camptothecin, the molar ratio is 25 0.00001 to 10, preferably 0.0001 to 1, to 1 of the benzamide derivative (said ingredient (a)). In the case of 5-fluorouracil, the molar ratio is 0.01 to 100000, preferably 0.1 to 10000, to 1 of the benzamide derivative. In the case of gemcitabine, the molar ratio is 0.00001 to 100, preferably 0.0001 to 10, to 1 of the benzamide derivative (said ingredient (a)). In the case 30 of paclitaxel, the molar ratio is 0.000001 to 0.01, preferably 0.00001 to 0.001, to 1 of the benzamide derivative (said ingredient (a)).

In the case of docetaxel, the molar ratio is 35 0.0000001 to 1, preferably 0.000001 to 0.1, to 1 of the benzamide derivative (said ingredient (a)).

In the case of carboplatin, the molar ratio is 0.001 to 10000, preferably 0.01 to 1000, to 1 of the benzamide

derivative (said ingredient (a)).

In the case of oxaliplatin, the molar ratio is 0.001 to 10000, preferably 0.01 to 1000, to 1 of the benzamide derivative (said ingredient (a)).

5 In the case of doxorubicin, the molar ratio is 0.000001 to 1, preferably 0.00001 to 0.1, to 1 of the benzamide derivative (said ingredient (a)).

10 In the case of vinblastin, the molar ratio is 0.000001 to 1, preferably 0.00001 to 0.1, to 1 of the benzamide derivative (said ingredient (a)).

An administration route of the pharmaceutical composition or combination is not limited, and selected depending on their dosage form, patient's age, sex, severity of disease and other conditions. For example, 15 tablet, pill, solution, suspension, emulsion, granule and capsule may be orally administered; injection may be intravenously administered solely or in combination with a common infusion fluid such as glucose, amino acids and the like, or if necessary, intramuscularly, 20 subcutaneously or intraperitoneally as a sole preparation. Suppository may be intrarectally administered.

Dose of the pharmaceutical composition or combination of this invention may be selected, depending 25 on their dosage form, patient's age, sex and severity of disease, and other conditions, as appropriate, and the amount of the active ingredients in the composition may be generally about 0.0001 to 1000 mg/kg a day. It is preferable that a unit dosage form may contain about 30 0.001 to 1000 mg of the active ingredient(s).

Further, in the case of pharmaceutical combinations, the amount of the active ingredient of the benzamide derivative (said ingredient (a)) may be about 0.0001 to 1000 mg per kg body weight. In the case of cisplatin, the 35 amount may be about 0.01 to 50 mg per kg body weight. In the case of etoposide, the amount may be about 0.1 to 10 mg per kg body weight. In the case of camptothecin, the

amount may be about 0.1 to 10 mg per kg body weight.

In the case of 5-fluorouracil, the amount may be about 0.1 to 200 mg per kg body weight.

5 In the case of gemcitabine, the amount may be about 1 to 300 mg per kg body weight. In the case of paclitaxel, the amount may be about 0.1 to 100 mg per kg body weight.

In the case of docetaxel, the amount may be about 0.1 to 50 mg per kg body weight.

10 In the case of carboplatin, the amount may be about 0.2 to 100 mg per kg body weight.

In the case of oxaliplatin, the amount may be about 0.1 to 50 mg per kg body weight.

15 In the case of doxorubicin, the amount may be about 0.1 to 50 mg per kg body weight.

In the case of vinblastin, the amount may be about 0.01 to 5 mg per kg body weight.

20 For administration of pharmaceutical combinations, in the case of simultaneous administration, the first active ingredient and the second active ingredient are administered without any time interval. In the case of administration at different times (consecutively), it is preferable to administer the first active ingredient and then administer the second active ingredient half a day  
25 to 60 days later.

#### EXAMPLES

Next, the present invention will be explained with examples more specifically.

30 Examples. Confirmation of Synergistic Effect Between Histone Deacetylase Inhibitor and Known Anticancer Active Substances on Cancer Cell Proliferation


35 The synergistic effects in combined use of the histone deacetylase inhibitor of the present invention and various types of known anticancer active substances on various types of cancer cell lines were confirmed by the examples.

#### Test Substances

As the histone deacetylase inhibitor of the present invention, N-(2-aminophenyl)4-[N-(pyridin-3-ylmethoxycarbonyl)aminomethyl]benzamide (MS-275) represented by the following formula (5) was used.

5

10



And, as known anticancer activity substances used in conjunction with the above MS-275 compound, paclitaxel (PTX), camptothecin (CPT), etoposide (VP-16), cisplatin (CDDP), gemcitabine (GEM), 5-fluorouracil (5-FU), docetaxel (DTX), carboplatin (CBDCA), oxaliplatin (OXP), doxorubicin (DOX), or vinblastin (VBL) was used.

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
3310  
3311  
3312  
3313  
3314  
3315  
3316  
3317  
3318  
3319  
3320  
3321  
3322  
3323  
3324  
3325  
3326  
3327  
3328  
3329  
3330  
3331  
3332  
3333  
3334  
3335  
3336  
3337  
3338  
3339  
3340  
3341  
3342  
3343  
3344  
3345  
3346  
3347  
3348  
3349  
3350  
3351  
3352  
3353  
3354  
3355  
3356  
3357  
3358  
3359  
33510  
33511  
33512  
33513  
33514  
33515  
33516  
33517  
33518  
33519  
33520  
33521  
33522  
33523  
33524  
33525  
33526  
33527  
33528  
33529  
33530  
33531  
33532  
33533  
33534  
33535  
33536  
33537  
33538  
33539  
33540  
33541  
33542  
33543  
33544  
33545  
33546  
33547  
33548  
33549  
33550  
33551  
33552  
33553  
33554  
33555  
33556  
33557  
33558  
33559  
33560  
33561  
33562  
33563  
33564  
33565  
33566  
33567  
33568  
33569  
33570  
33571  
33572  
33573  
33574  
33575  
33576  
33577  
33578  
33579  
33580  
33581  
33582  
33583  
33584  
33585  
33586  
33587  
33588  
33589  
33590  
33591  
33592  
33593  
33594  
33595  
33596  
33597  
33598  
33599  
335100  
335101  
335102  
335103  
335104  
335105  
335106  
335107  
335108  
335109  
335110  
335111  
335112  
335113  
335114  
335115  
335116  
335117  
335118  
335119  
335120  
335121  
335122  
335123  
335124  
335125  
335126  
335127  
335128  
335129  
335130  
335131  
335132  
335133  
335134  
335135  
335136  
335137  
335138  
335139  
335140  
335141  
335142  
335143  
335144  
335145  
335146  
335147  
335148  
335149  
335150  
335151  
335152  
335153  
335154  
335155  
335156  
335157  
335158  
335159  
335160  
335161  
335162  
335163  
335164  
335165  
335166  
335167  
335168  
335169  
335170  
335171  
335172  
335173  
335174  
335175  
335176  
335177  
335178  
335179  
335180  
335181  
335182  
335183  
335184  
335185  
335186  
335187  
335188  
335189  
335190  
335191  
335192  
335193  
335194  
335195  
335196  
335197  
335198  
335199  
335200  
335201  
335202  
335203  
335204  
335205  
335206  
335207  
335208  
335209  
335210  
335211  
335212  
335213  
335214  
335215  
335216  
335217  
335218  
335219  
335220  
335221  
335222  
335223  
335224  
335225  
335226  
335227  
335228  
335229  
335230  
335231  
335232  
335233  
335234  
335235  
335236  
335237  
335238  
335239  
335240  
335241  
335242  
335243  
335244  
335245  
335246  
335247  
335248  
335249  
335250  
335251  
335252  
335253  
335254  
335255  
335256  
335257  
335258  
335259  
335260  
335261  
335262  
335263  
335264  
335265  
335266  
335267  
335268  
335269  
335270  
335271  
335272  
335273  
335274  
335275  
335276  
335277  
335278  
335279  
335280  
335281  
335282  
335283  
335284  
335285  
335286  
335287  
335288  
335289  
335290  
335291  
335292  
335293  
335294  
335295  
335296  
335297  
335298  
335299  
335300  
335301  
335302  
335303  
335304  
335305  
335306  
335307  
335308  
335309  
335310  
335311  
335312  
335313  
335314  
335315  
335316  
335317  
335318  
335319  
335320  
335321  
335322  
335323  
335324  
335325  
335326  
335327  
335328  
335329  
335330  
335331  
335332  
335333  
335334  
335335  
335336  
335337  
335338  
335339  
335340  
335341  
335342  
335343  
335344  
335345  
335346  
335347  
335348  
335349  
335350  
335351  
335352  
335353  
335354  
335355  
335356  
335357  
335358  
335359  
335360  
335361  
335362  
335363  
335364  
335365  
335366  
335367  
335368  
335369  
335370  
335371  
335372  
335373  
335374  
335375  
335376  
335377  
335378  
335379  
335380  
335381  
335382  
335383  
335384  
335385  
335386  
335387  
335388  
335389  
335390  
335391  
335392  
335393  
335394  
335395  
335396  
335397  
335398  
335399  
335400  
335401  
335402  
335403  
335404  
335405  
335406  
335407  
335408  
335409  
335410  
335411  
335412  
335413  
335414  
335415  
335416  
335417  
335418  
335419  
335420  
335421  
335422  
335423  
335424  
335425  
335426  
335427  
335428  
335429  
335430  
335431  
335432  
335433  
335434  
335435  
335436  
335437  
335438  
335439  
335440  
335441  
335442  
335443  
335444  
335445  
335446  
335447  
335448  
335449  
335450  
335451  
335452  
335453  
335454  
335455  
335456  
335457  
335458  
335459  
335460  
335461  
335462  
335463  
335464  
335465  
335466  
335467  
335468  
335469  
335470  
335471  
335472  
335473  
335474  
335475  
335476  
335477  
335478  
335479  
335480  
335481  
335482  
335483  
335484  
335485  
335486  
335487  
335488  
335489  
335490  
335491  
335492  
335493  
335494  
335495  
335496  
335497  
335498  
335499  
335500  
335501  
335502  
335503  
335504  
335505  
335506  
335507  
335508  
335509  
335510  
335511  
335512  
335513  
335514  
335515  
335516  
335517  
335518  
335519  
335520  
335521  
335522  
335523  
335524  
335525  
335526  
335527  
335528  
335529  
335530  
335531  
335532  
335533  
335534  
335535  
335536  
335537  
335538  
335539  
335540  
335541  
335542  
335543  
335544  
335545  
335546  
335547  
335548  
335549  
335550  
335551  
335552  
335553  
335554  
335555  
335556  
335557  
335558  
335559  
335560  
335561  
335562  
335563  
335564  
335565  
335566  
335567  
335568  
335569  
335570  
335571  
335572  
335573  
335574  
335575  
335576  
335577  
335578  
335579  
335580  
335581  
335582  
335583  
335584  
335585  
335586  
335587  
335588  
335589  
335590  
335591  
335592  
335593  
335594  
335595  
335596  
335597  
335598  
335599  
3355100  
3355101  
3355102  
3355103  
3355104  
3355105  
3355106  
3355107  
3355108  
3355109  
3355110  
3355111  
3355112  
3355113  
3355114  
3355115  
3355116  
3355117  
3355118  
3355119  
3355120  
3355121  
3355122  
3355123  
3355124  
3355125  
3355126  
3355127  
3355128  
3355129  
3355130  
3355131  
3355132  
3355133  
3355134  
3355135  
3355136  
3355137  
3355138  
3355139  
3355140  
3355141  
3355142  
3355143  
3355144  
3355145  
3355146  
3355147  
3355148  
3355149  
3355150  
3355151  
3355152  
3355153  
3355154  
3355155  
3355156  
3355157  
3355158  
3355159  
3355160  
3355161  
3355162  
3355163  
3355164  
3355165  
3355166  
3355167  
3355168  
3355169  
3355170  
3355171  
3355172  
3355173  
3355174  
3355175  
3355176  
3355177  
3355178  
3355179  
3355180  
3355181  
3355182  
3355183  
3355184  
3355185  
3355186  
3355187  
3355188  
3355189  
3355190  
3355191  
3355192  
3355193  
3355194  
3355195  
3355196  
3355197  
3355198  
3355199  
3355200  
3355201  
3355202  
3355203  
3355204  
3355205  
3355206  
3355207  
3355208  
3355209  
3355210  
3355211  
3355212  
3355213  
3355214  
3355215  
3355216  
3355217  
3355218  
3355219  
3355220  
3355221  
3355222  
3355223  
3355224  
3355225  
3355226  
3355227  
3355228  
3355229  
3355230  
3355231  
3355232  
3355233  
3355234  
3355235  
3355236  
3355237  
3355238  
3355239  
3355240  
3355241  
3355242  
3355243  
3355244  
3355245  
3355246  
3355247  
3355248  
3355249  
3355250  
3355251  
3355252  
3355253  
3355254  
3355255  
3355256  
3355257  
3355258  
3355259  
3355260  
3355261  
3355262  
3355263  
3355264  
3355265  
3355266  
3355267  
3355268  
3355269  
3355270  
3355271  
3355272  
3355273  
3355274  
3355275  
3355276  
3355277  
3355278  
3355279  
3355280  
3355281  
3355282  
3355283  
3355284  
3355285  
3355286  
3355287  
3355288  
3355289  
3355290  
3355291  
3355292  
3355293  
3355294  
3355295  
3355296  
3355297  
3355298  
3355299  
3355300  
3355301  
3355302  
3355303  
3355304  
3355305  
3355306  
3355307  
3355308  
3355309  
3355310  
3355311  
3355312  
3355313  
3355314  
3355315  
3355316  
3355317  
3355318  
3355319  
3355320  
3355321  
3355322  
3355323  
3355324  
3355325  
3355326  
3355327  
3355328  
3355329  
3355330  
3355331  
3355332  
3355333  
3355334  
3355335  
3355336  
3355337  
3355338  
3355339  
3355340  
3355341  
3355342  
3355343  
3355344  
3355345  
3355346  
3355347  
3355348  
3355349  
3355350  
3355351  
3355352  
3355353  
3355354  
3355355  
3355356  
3355357  
3355358  
3355359  
3355360  
3355361  
3355362  
3355363  
3355364  
3355365  
3355366  
3355367  
3355368  
3355369  
3355370  
3355371  
3355372  
3355373  
3355374  
3355375  
3355376  
3355377  
3355378  
3355379  
3355380  
3355381  
3355382  
3355383  
3355384  
3355385  
3355386  
3355387  
3355388  
3355389  
3355390  
3355391  
3355392  
3355393  
3355394  
3355395  
3355396  
3355397  
3355398  
3355399  
3355400  
3355401  
3355402  
3355403  
3355404  
3355405  
3355406  
3355407  
3355408  
3355409  
3355410  
3355411  
3355412  
3355413  
3355414  
3355415  
3355416  
3355417  
3355418  
3355419  
3355420  
3355421  
3355422  
3355423  
3355424  
3355425  
3355426  
3355427  
3355428  
3355429  
3355430  
3355431  
3355432  
3355433  
3355434  
3355435  
3355436  
3355437  
3355438  
3355439  
3355440  
3355441  
3355442  
3355443  
3355444  
3355445  
3355446  
3355447  
3355448  
3355449  
3355450  
3355451  
3355452  
3355453  
3355454  
3355455  
3355456  
3355457  
3355458  
3355459  
3355460  
3355461  
3355462  
3355463  
3355464  
3355465  
3355466  
3355467  
3355468  
3355469  
3355470  
3355471  
3355472  
3355473  
3355474  
3355475  
3355476  
3355477  
3355478  
3355479  
3355480  
3355481  
3355482  
3355483  
3355484  
3355485  
3355486  
3355487  
3355488  
3355489  
3355490  
3355491  
3355492  
3355493  
3355494  
3355495  
3355496  
3355497  
3355498  
3355499  
3355500  
3355501  
3355502  
3355503  
3355504  
3355505  
3355506  
3355507  
3355508  
3355509  
3355510  
3355511  
3355512  
3355513  
3355514  
3355515  
3355516  
3355517  
3355518  
3355519  
3355520  
3355521  
3355522  
3355523  
3355524  
3355525  
3355526  
3355527  
3355528  
3355529  
3355530  
3355531  
3355532  
3355533  
3355534  
3355535  
3355536  
3355537  
3355538  
3355539  
3355540  
3355541  
3355542  
3355543  
3355544  
3355545  
3355546  
3355547  
3355548  
3355549  
33555410  
33555411  
33555412  
33555413  
33555414  
33555415  
33555416  
33555417  
33555418  
33555419  
33555420  
33555421  
33555422  
33555423  
33555424  
33555425  
33555426  
33555427  
33555428  
33555429  
33555430  
33555431  
335

In this method, the test cancer cells were incubated for 72 to 120 hours in a medium containing a mixture of MS-275 and another known anticancer active substance, and then the surviving cancer cells were measured.

5           Consecutively Combined Use:

In this method, the test cancer cells were incubated for 24 hours in a medium containing one of the test substances, and the medium containing said test substance was aspirated at this point of time. Then the cells were 10 incubated for 24 hours in a medium containing the other of the test substances, the medium containing said test substance was aspirated at this point of time, then the cells were incubated for another 72 hours in a medium not containing the test substances, and then the surviving 15 cancer cells were measured. In the consecutively combined use, the MS-275 was made to act in the first 24 hours and the other known anticancer active substance was made to act in the succeeding 24 hours. And in the reversed order of what was made to act this experiment was performed. 20 Further, in the single administration control for the combined use, the test substance was made to act in only the initial 24 hours or the succeeding 24 hours. In another 24 hour period and the final 72 hours, the cells were incubated in the absence of the test substance, and 25 then the surviving cancer cells were measured.

Method of Measurement of Surviving Cancer Cells

After the above treatment (incubation) of the cancer cells by the test substances was ended, the surviving cells were measured by one of the following two methods.

30           Neutral Red Assay:

In this measurement method the following property is utilized; only surviving cells can take a water soluble dye, Neutral Red, into the cells. The above treatment of cancer cells by the test substance was performed in 35 wells. A Neutral Red solution (1 mg/ml in PBS) was added into the wells after the end of the treatment (incubation). The incubation at 37°C for one hour allowed

the Neutral Red to be taken into the cells. The solution was aspirated and 100% ethanol and 0.1M NaH<sub>2</sub>PO<sub>4</sub> were added to the wells. The Neutral Red taken into the cells was extracted from the cells and then the extracted  
5 Neutral Red was measured by a microplate reader at 540 nm.

**MTS Assay:**

This method is to investigate cell survivability by utilizing the fact that MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenol)-2-(4-sulfonyl)-2H-tetrazoliumm) is metabolized to formazan by mitochondria dehydrogenase existing in surviving cells. In this method the experiment was performed using a Cell Titer 96  
10 (trademark) aqueous one solution cell proliferation assay (trademark) of Promega in accordance with the instructions attached to the reagents.  
15

Combined Ratio of Test Substances and Judgment of Synergism

The combined ratio of the test substances was determined as follows: In the graph of FIG. 1, the abscissa shows the log (Log M) of the concentrations of the test substances, and the ordinate shows the relative survival rate in the case indexed to the surviving tested cancer cells in the case of zero concentration of test  
20 substances. Graphs of the concentration of the test substances and the relative survival rate of the tested cancer cells in the case of the test substances alone were made. The concentrations of the test substances in the case of relative survival rates of 50%, IC<sub>50</sub>, were  
25 calculated.  
30

Regarding the IC<sub>50</sub>'s of the test substances A and B for which the existence of a synergistic effect was desired to be learned, in the case that the IC<sub>50</sub> of the test substance A was 1 μM and 0.01 μM as the IC<sub>50</sub> of the test substance B was 0.01 μM, since the anticancer effect  
35 of the test substance B was 100 times that of the test

substance A, the combined ratio of the test substance A and test substance B was made 100:1. This ratio was kept constant across the various total concentrations of the test substances. However, the IC<sub>50</sub> of a test substance  
5 differed according to the tested cancer cells, so the combined ratio needed to be determined for each test substance and for each type of tested cancer cells.

In FIG. 1, the "concentration-survival rate curve" of the test substance A was shown in a solid line, and  
10 the "concentration-survival rate curve" of the test substance B was shown in a dotted line. Further, given that the test substance A and test substance B were used in a constant ratio (for example, 100:1) and at various total concentrations and that the combined effect of the  
15 test substances was "additive", a "concentration-survival rate curve" could be drawn for the case of combined use by calculation. For example, in FIG. 1, this could be shown in a series of black dots.

On the other hand, an actual "concentration-survival rate curve" could be drawn by calculating from the actually measured values in the case of use of the test substance A and test substance B at a constant ratio (for example, 100:1) but at various total concentrations. When the curve is present at the left side from the  
20 "concentration-survival rate curve" drawn by calculation under the assumption of "additive" as shown for example by a series of black squares in FIG. 1, the combined effects of the test substance A and the test substance B were judged to be "synergistic". Meanwhile, when the  
25 actual "concentration-survival rate curve" was drawn at the right side from the "concentration-survival rate curve" drawn by calculation under the assumption of "additive" as shown for example by a series of black triangles in FIG. 1, the combined effects of the test substance A and the test substance B were judged to be  
30 "antagonistic".

In actuality, the combination index (CI) was

calculated from the measurement results by the method described in Chou TC et al., *Adv. Enzyme Regul.* 22: 27-55 (1984) (Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors). In this case, when the combined effects of the test substance A and test substance B were additive, CI=1. When CI was less than 1, the effects were synergistic. When CI was more than one, the effects were antagonistic. Further, the following were judged; the smaller a value less than 1 was the higher the "synergism" was. And the greater a value more than 1 was, the higher the "antagonism" was.

Further, the relationship between the range of the CI value and the degree of synergism and antagonism is expressed as follows:

Table 1

Range of CI value	Symbol	Description
<0.1	++++	Very strongly synergistic
0.1 to 0.3	+++	Strongly synergistic
0.3 to 0.7	++	Synergistic
0.7 to 0.85	+	Moderately synergistic
0.85 to 0.9	+	Slightly synergistic
0.9 to 1.1	±	Additive
1.1<	-	Antagonistic

#### RESULTS

The ratios between MS-275 and other anticancer active substances with respect to each tested cancer cell line in the case of simultaneous combined use are as follows:

- 23 -

Table 2

Ratio of MS-275 and Other Anticancer Active Substances  
(X) in Simultaneous Combined Use

Cancer cell line		Time (hr)	Ratio (MS-275:X)					
			PTX	CPT	VP-16	CDDP	GEM	5-FU
Colon cancer	HT-29	72		30:1		1:5	5:1	1:10
	HCT116	72		50:1	1:1	1:10	100:1	1:10
Non-small cell lung cancer	NCI-H522	72	200:1				500:1	
		120	400:1				2000:1	
Ovarian cancer	A549	72	100:1			1:10	40:1	
	SK-OV-3	72	1000:1	100:1	1:1	1:2		
		120	1000:1	100:1	1:1	1:2		
Pan-creatic cancer	OVCAR-3	120	1000:1	100:1	4:1	1:1	200:1	
	PANC-1	72	2000:1	200:1		1:1	200:1	1:1
		120	2000:1	400:1		1:1	200:1	1:1
Breast cancer	MCF-7	72	400:1					1:10
		120	400:1					1:10
Prostate cancer	PC-3	72	100:1		1:40			
		120	10:1		1:50			

5

The results in the case of simultaneous combined use are as follows:

Table 3

Synergistic Effect in Combined Use of MS-275 and Other  
Anticancer Active Substances in Simultaneous Combined Use

Cancer cell line	Time (hr)	Other anticancer active substance					
		PTX	CPT	VP-16	CDDP	GEM	5-FU
Colon cancer	HT-29	72	-	-	-	-	-
		72					+++
HCT116	72		-	-	-	-	-
Non-small cell lung cancer	NCI-H522	72	-			±	
		120	-			-	
		72				±	
	A549	72	-			-	-
		72				+++	
	Calu-1	72				+++	
	Calu-3	72				+++	
	A-427	72				-	
	NCI-H23	72				+++	
	NCI-H358	72				±	
	NCI-H460	72				+++	
Ovarian cancer	SK-OV-3	72	-	-	+++	++	
		120	-	-	±	-	
OVCAR-3	120	-	-	-	-	-	
Pan-creatic cancer	PANC-1	72	-	+++		++	+++
		120	-	-		++	-
Breast cancer	MCF-7	72					+++
		120	-				++
Pro-state cancer	PC-3	72	-		-		
		120	++		-		

5        As explained above, the combined effects of MS-275 and another known anticancer drug PTX, CPT, VP-16, GEM, or 5-FU were detected in specific cancer cells. Further, the combined effects of MS-275 and CDDP were detected in a broad range of cancer cells.

10      Further, the results in the case of consecutive combined use are shown in Table 4 (combined use of MS-275 and PTX), Table 5 (combined use of MS-275 and GEM), Table 6 (combined use of MS-275 and CDDP), Table 7 (combined use of MS-275 and CPT), Table 8 (combined use of MS-275 and DTX), Table 9 (combined use of MS-275 and CBDCA), Table 10 (combined use of MS-275 and OXP), Table 11 (combined use of MS-275 and DOX), Table 12 (combined use of MS-275 and VBL), and Table 13 (combined use of MS-275

- 25 -

and 5-FU). Note that in these tables, "Ratio 275:XS" means the ratio of MS-275 and another anticancer active substance (X), while "275->X->f" indicates treatment by MS-275 in the initial treatment period of 24 hours, 5 treatment by another anticancer active substance in the following treatment period of 24 hours, then incubation in a medium not containing the test substance for 72 hours. Further, "X->275->f" indicates treatment by another anticancer active substance in the initial 10 treatment period of 24 hours, treatment by MS-275 in the following treatment period of 24 hours, then incubation in a medium not containing the test substance for 72 hours. Further, the numerical values showing the synergistic effect show the CI values.

15

Table 4  
Synergistic Effect in Consecutive Combined Use of MS-275  
and PTX

Cancer cell line		Time (hr)	Ratio 275:X	Order of consecutive combined use	
				275->X->f	X->275->f
Ovarian cancer	SK-OV-3	24+24+72	1000:1	1.1< -	0.76 ++
Breast cancer	T-47D	24+24+72	1000:1		0.71 ++

- 26 -

Table 5

Synergistic Effect in Consecutive Combined Use of MS-275  
and GEM

Cancer cell line		Time (hr)	Ratio 275:X	Order of consecutive combined use	
				275->X->f	X->275->f
Colon cancer	HT-29	24+24+72	200:1	1.1< - -	0.48 +++
Non-small cell lung cancer	NCI-H522	24+24+72	200:1	0.75 ++	1.1< - -
	NCI-H522	24+24+72	3000:1		0.77 ++
	A549	24+24+72	100:1	1.1< - -	0.69 +++
Ovarian cancer	OVCAR-3	24+24+72	400:1	1.1 - -	0.54 +++
	SK-OV3	24+24+72	5000:1		0.56 +++
Pancreatic cancer	PANC-1	24+24+72	50000:1		0.59 +++

5

Table 6

Synergistic Effect in Consecutive Combined Use of MS-275  
and CDDP

Cancer cell line		Time (hr)	Ratio 275:X	Order of consecutive combined use	
				275->X->f	X->275->f
Colon cancer	HCT116	24+24+72	1:8	0.63 +++	0.95 ±
	HT-29	24+24+72	4:1		0.89 +
Non-small cell lung cancer	NCI-H522	24+24+72	1:1	0.55 +++	0.69 +++
	A549	24+24+72	1:4	0.66 +++	0.42 +++
Ovarian cancer	SK-OV3	24+24+72	1:1	0.43 +++	0.57 +++
	OVCAR-3	24+24+72	1:1	0.77 ++	0.61 +++
Pancreatic cancer	PANC-1	24+24+72	8:1	0.96 ±	0.45 +++
	Capan-1	24+24+72	1:1	0.53 +++	0.63 +++

- 27 -

Table 7

Synergistic Effect in Consecutive Combined Use of MS-275  
and CPT

Cancer cell line		Time (hr)	Ratio 275:X	Order of consecutive combined use	
				275->X->f	X->275->f
Colon cancer	HCT116	24+24+72	100:1	0.91 ±	0.85 ++
Non-small cell lung cancer	NCI-H522	24+24+72	100:1	0.31 +++	0.92 ±
	A549	24+24+72	25:1	1.1< -	0.79 ++
Ovarian cancer	OVCAR-3	24+24+72	200:1	1.05 ±	0.26 +***
	SK-OV3	24+24+72	2000:1		0.72 ++
Pancreatic cancer	Capan-1	24+24+72	200:1	1.1< -	0.49 +**

5

Table 8

Synergistic Effect in Consecutive Combined Use of MS-275 and DTX (Docetaxel)

Cancer cell line		Time (hr)	Ratio 275:X	Order of consecutive combined use	
				275->X->f	X->275->f
Non-small cell lung cancer	A549	24+24+72	10000:1		0.87 +
Ovarian cancer	SK-OV3	24+24+72	20000:1		0.87 +
Pancreatic cancer	Capan-1	24+24+72	3000:1		0.87 +
Prostate cancer	PC-3	24+24+72	300:1		0.89 +

Table 9

Synergistic Effect in Consecutive Combined Use of MS-275  
Compound and CBDCA (Carboplatin)

Cancer cell line		Time (hr)	Ratio 275:X	Order of consecutive combined use	
				275->X->f	X->275->f
Non-small cell lung cancer	A549	24+24+72	1:10		0.31 +++
	NCI-H522	24+24+72	1:2		0.86 +
Ovarian cancer	SK-OV3	24+24+72	3:2		0.59 +++
Pancreatic cancer	Capan-1	24+24+72	1:1		0.47 +++
	PANC-1	24+24+72	1:1		0.30 ++++

5

Table 10

Synergistic Effect in Consecutive Combined Use of MS-275  
and OXP (Oxaliplatin)

Cancer cell line		Time (hr)	Ratio 275:X	Order of consecutive combined use	
				275->X->f	X->275->f
Colon cancer	HT-29	24+24+72	5:1		0.77 ++
Ovarian cancer	SK-OV3	24+24+72	2:1		0.83 ++

Table 11

10 Synergistic Effect in Consecutive Combined Use of MS-275  
and DOX (Doxorubicin)

Cancer cell line		Time (hr)	Ratio 275:X	Order of consecutive combined use	
				275->X->f	X->275->f
Ovarian cancer	SK-OV3	24+24+72	300:1		0.86 +

- 29 -

Table 12

Synergistic Effect in Consecutive Combined Use of MS-275  
and VBL (Vinblastin)

Cancer cell line	Time (hr)	Ratio 275:X	Order of consecutive combined use	
			275->X->f	X->275->f
Non-small cell lung cancer	A549	24+24+72	300:1	0.89 +

5

Table 13

Synergistic Effect in Consecutive Combined Use of MS-275  
and 5-FU (5-Fluorouracil)

Cancer cell line	Time (hr)	Ratio 275:X	Order of consecutive combined use	
			275->X->f	X->275->f
Colon cancer	HT-29	24+24+72	2:3	0.79 ++

In each case of each of the tested anticancer active substances, synergistic effects due to combined use with MS-275 were detected.

10

INDUSTRIAL APPLICABILITY


15

As explained above, synergistic effects are recognized in in vitro tests between histone deacetylase inhibitors as represented by MS-275 and other various types of known anticancer active substances, so it is suggested that synergistic effects will be obtained in treatment for human cancer patient as well.

CLAIMS

1. A pharmaceutical composition or a combination comprising, as active ingredients:

5 (a) at least one of the benzamide derivatives which is a histone deacetylase inhibiting substance, or a pharmaceutically acceptable salt thereof, represented by the following formula (1):




15 wherein A is an optionally substituted phenyl group or an optionally substituted heterocyclic group wherein the substituent(s) for the phenyl group or the heterocyclic group is (are) 1 to 4 substituents selected from the group consisting of a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, an alkyl group having 1 to 4 carbons, an alkoxy group having 1 to 4 carbons, an aminoalkyl group having 1 to 4 carbons, an alkylamino group having 1 to 4 carbons, an acyl group having 1 to 4 carbons, an acylamino group having 1 to 4 carbons, an alkylthio group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a perfluoroalkyloxy group having 1 to 4 carbons, a carboxyl group, an alkoxy carbonyl group having 1 to 4 carbons, a phenyl group and a heterocyclic group;

20

25 X is a bond or a moiety having a structure selected from those illustrated in formula (2):

- 31 -






wherein e is an integer of 1 to 4; g and m are independently an integer of 0 to 4; R4 is a hydrogen atom or an optionally substituted alkyl group having 1 to 4 carbons, or the acyl group represented by formula (3)



wherein R6 is an optionally substituted alkyl group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a phenyl group or a heterocyclic group; R5 is a hydrogen atom or an optionally substituted alkyl group having 1 to 4 carbons;

n is an integer of 0 to 4, provided that when X is a bond, n is not zero;

Q is a moiety having a structure selected from those illustrated in formula (4)



wherein R7 and R8 are independently a hydrogen atom or an optionally substituted alkyl group having 1 to 4 carbons;





15 R1 and R2 are independently a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, an alkyl group having 1 to 4 carbons, an alkoxy group having 1 to 4 carbons, an aminoalkyl group having 1 to 4 carbons, an alkylamino group having 1 to 4 carbons, an acyl group having 1 to 4 carbons, an acylamino group having 1 to 4 carbons, an alkylthio group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a perfluoroalkyloxy group having 1 to 4 carbons, a carboxyl group or an alkoxy carbonyl group having 1 to 4 carbons;

20 R3 is a hydroxyl group or amino group, and

25 (b) at least one of the substances which is another anti-cancer active substance selected from a group consisting of cisplatin, etoposide, camptothecin, 5-fluorouracil, gemcitabine, paclitaxel, docetaxel, carboplatin, oxaliplatin, doxorubicin and vinblastin.


30 2. A pharmaceutical composition or a combination according to claim 1 wherein said benzamide derivative is selected from formulas (5) to (8) or a pharmaceutically acceptable salt thereof.

- 33 -



3. A pharmaceutical composition or a combination according to claim 1 or 2 wherein said benzamide derivative is represented by formula (5) or a pharmaceutically acceptable salt thereof.

5



(5)

4. A pharmaceutical composition or a combination  
10 according to any one of claims 1 to 3 wherein a substance  
selected from a group of substances consisting of said  
ingredient (b) which is another anti-cancer active  
substance is cisplatin.

5. A pharmaceutical composition or a combination  
15 according to claim 4, which is used for treatment of non-  
small cell lung cancer, ovarian cancer, colon cancer or  
pancreatic cancer.

6. A pharmaceutical composition or a combination  
20 according to any one of claims 1 to 3 wherein a substance  
selected from a group of substances consisting of said  
ingredient (b) which is another anti-cancer active  
substance is etoposide.

7. A pharmaceutical composition or a combination  
25 according to claim 6, which is used for treatment of  
ovarian cancer.

8. A pharmaceutical composition or a combination  
according to any one of claims 1 to 3 wherein a substance  
selected from a group of substances consisting of said  
ingredient (b) which is another anti-cancer active  
30 substance is camptothecin.

9. A pharmaceutical composition or a combination  
according to claim 8, which is used for treatment of non-  
small cell lung cancer, ovarian cancer, colon cancer or  
pancreatic cancer.

35 10. A pharmaceutical composition or a combination  
according to any one of claims 1 to 3 wherein a substance  
selected from a group of substances consisting of said

ingredient (b) which is another anti-cancer active substance is 5-fluorouracil.

5        11. A pharmaceutical composition or a combination according to claim 10, which is used for treatment of breast cancer or colon cancer.

10      12. A pharmaceutical composition or a combination according to any one of claims 1 to 3 wherein a substance selected from a group of substances consisting of said ingredient (b) which is another anti-cancer active substance is gemcitabine.

15      13. A pharmaceutical composition or a combination according to claim 12, which is used for treatment of non-small cell lung cancer, ovarian cancer, colon cancer or pancreatic cancer.

20      14. A pharmaceutical composition or a combination according to any one of claims 1 to 3 wherein a substance selected from a group of substances consisting of said ingredient (b) which is another anti-cancer active substance is paclitaxel.

25      15. A pharmaceutical composition or a combination according to claim 14, which is used for treatment of breast cancer, ovarian cancer or prostate cancer.

30      16. A pharmaceutical composition or a combination according to any one of claims 1 to 3 wherein a substance selected from a group of substances consisting of said ingredient (b) which is another anti-cancer active substance is docetaxel.

35      17. A pharmaceutical composition or a combination according to claim 16, which is used for treatment of non-small cell lung cancers, ovarian cancer, pancreatic cancer and prostate cancer.

40      18. A pharmaceutical composition or a combination according to any one of claims 1 to 3 wherein a substance selected from a group of substances consisting of said ingredient (b) which is another anti-cancer active substance is carboplatin.

45      19. A pharmaceutical composition or a combination

according to claim 18, which is used for treatment of non-small cell lung cancer, ovarian cancer, or pancreatic cancer.

20. A pharmaceutical composition or a combination  
5 according to any one of claims 1 to 3 wherein a substance selected from a group of substances consisting of said ingredient (b) which is another anti-cancer active substance is oxaliplatin.

21. A pharmaceutical composition or a combination  
10 according to claim 20, which is used for treatment of colon cancer or ovarian cancer.

22. A pharmaceutical composition or a combination according to any one of claims 1 to 3 wherein a substance selected from a group of substances consisting of said 15 ingredient (b) which is another anti-cancer active substance is doxorubicin.

23. A pharmaceutical composition or a combination according to claim 22, which is used for treatment of ovarian cancer.

20 24. A pharmaceutical composition or a combination according to any one of claims 1 to 3 wherein a substance selected from a group of substances consisting of said ingredient (b) which is another anti-cancer active substance is vinblastin.

25 25. A pharmaceutical composition or a combination according to claim 24, which is used for treatment of non-small cell lung cancer.

30 26. A pharmaceutical combination according to any one of claims 1 to 25, of which said ingredient (a) which is a histone deacetylase inhibiting substance and said ingredient (b) which is another anti-cancer active substance are sequentially administered to patients.

27. A pharmaceutical combination according to claim 35 26, wherein said ingredient (b) which is another anti-cancer active substance is paclitaxel.

28. A pharmaceutical combination according to claim 27, of which the administration sequence is paclitaxel

and then said ingredient (a) which is a histone deacetylase inhibiting substance.

29. A pharmaceutical combination according to claim 28, which is used for treatment of ovarian cancer or  
5 breast cancer.

30. A pharmaceutical combination according to claim 26, wherein said ingredient (b) which is another anti-cancer active substance is cisplatin.

31. A pharmaceutical combination according to claim 10 30, of which the administration sequence is said ingredient (a) which is a histone deacetylase inhibiting substance and then cisplatin.

32. A pharmaceutical combination according to claim 15 31, which is used for treatment of non-small cell lung cancer, ovarian cancer, colon cancer or pancreatic cancer.

33. A pharmaceutical combination according to claim 20 30, of which the administration sequence is cisplatin and then said ingredient (a) which is a histone deacetylase inhibiting substance.

34. A pharmaceutical combination according to claim 33, which is used for treatment of non-small cell lung cancer, ovarian cancer, colon cancer or pancreatic cancer.

25 35. A pharmaceutical combination according to claim 26, wherein said ingredient (b) which is another anti-cancer active substance is camptothecin.

30 36. A pharmaceutical combination according to claim 35, of which the administration sequence is said ingredient (a) which is a histone deacetylase inhibiting substance and then camptothecin.

37. A pharmaceutical combination according to claim 36, which is used for treatment of non-small cell lung cancer.

35 38. A pharmaceutical combination according to claim 35, of which the administration sequence is camptothecin and then said ingredient (a) which is a histone

deacetylase inhibiting substance.

39. A pharmaceutical combination according to claim 38, which is used for treatment of non-small cell lung cancer, ovarian cancer, colon cancer or pancreatic cancer.

5 40. A pharmaceutical combination according to claim 26, wherein said ingredient (b) which is another anti-cancer active substance is gemcitabine.

10 41. A pharmaceutical combination according to claim 40, of which the administration sequence is said ingredient (a) which is a histone deacetylase inhibiting substance and then gemcitabine.

15 42. A pharmaceutical combination according to claim 41, which is used for treatment of non-small cell lung cancer.

43. A pharmaceutical combination according to claim 40, of which the administration sequence is gemcitabine and then said ingredient (a) which is a histone deacetylase inhibiting substance.

20 44. A pharmaceutical combination according to claim 43, which is used for treatment of non-small cell lung cancer, ovarian cancer, pancreatic cancer or colon cancer.

25 45. A pharmaceutical combination according to claim 26, wherein said ingredient (b) which is another anti-cancer active substance is 5-fluorouracil.

30 46. A pharmaceutical combination according to claim 45, of which the administration sequence is 5-fluorouracil and then said ingredient (a) which is a histone deacetylase inhibiting substance.

47. A pharmaceutical combination according to claim 46 which is used for treatment of colon cancer.

35 48. A pharmaceutical combination according to claim 26, wherein said ingredient (b) which is another anti-cancer active substance is docetaxel.

49. A pharmaceutical combination according to claim 48, of which the administration sequence is docetaxel and

then said ingredient (a) which is a histone deacetylase inhibiting substance.

5 50. A pharmaceutical combination according to claim 49 which is used for treatment of non-small cell lung cancer, ovarian cancer, pancreatic cancer or prostate cancer.

10 51. A pharmaceutical combination according to claim 26, wherein said ingredient (b) which is another anti-cancer active substance is carboplatin.

15 52. A pharmaceutical combination according to claim 51, of which the administration sequence is carboplatin and then said ingredient (a) which is a histone deacetylase inhibiting substance.

53. A pharmaceutical combination according to claim 15 52 which is used for treatment of non-small cell lung cancer, ovarian cancer or pancreatic cancer.

54. A pharmaceutical combination according to claim 26, wherein said ingredient (b) which is another anti-cancer active substance is oxaliplatin.

20 55. A pharmaceutical combination according to claim 54, of which the administration sequence is oxaliplatin and then said ingredient (a) which is a histone deacetylase inhibiting substance.

25 56. A pharmaceutical combination according to claim 55 which is used for treatment of colon cancer or ovarian cancer.

57. A pharmaceutical combination according to claim 26, wherein said ingredient (b) which is another anti-cancer active substance is doxorubicin.

30 58. A pharmaceutical combination according to claim 57, of which the administration sequence is doxorubicin and then said ingredient (a) which is a histone deacetylase inhibiting substance.

35 59. A pharmaceutical combination according to claim 58 which is used for treatment of ovarian cancer.

60. A pharmaceutical combination according to claim 26, wherein said ingredient (b) which is another anti-

cancer active substance is vinblastin.

61. A pharmaceutical combination according to claim 60, of which the administration sequence is vinblastin and then said ingredient (a) which is a histone deacetylase inhibiting substance.

5 62. A pharmaceutical combination according to claim 61 which is used for treatment of non-small cell lung cancer.

10 63. A cancer treatment kit comprising a pharmaceutical combination according to any one of claims 1 - 62, which comprises:


(i) at least one of said ingredients (a) which is a histone deacetylase inhibiting substance,

15 (ii) at least one of said ingredients (b) which is another anti-cancer active substance, and

(iii) an instruction for administration schedule for simultaneous or sequential administration according to a kind of cancer (for sequential administration to a patient at periodic intervals).

1/1

Fig.1



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP2004/007562

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/4406 A61K33/24 A61K31/282 A61K31/70 A61K31/4745
A61K31/513 A61K31/7068 A61K31/337 A61K31/555 A61K31/704
A61P35/00 A61K31/475
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 273 296 A (WARNER LAMBERT CO) 8 January 2003 (2003-01-08)  paragraphs '0003!, '0004!, '0011! - '0013!, '0032!; claims -----	1, 16, 17, 26, 48-50, 63
X	US 2003/083366 A1 (GROVE WILLIAM RICHARD ET AL) 1 May 2003 (2003-05-01)  paragraphs '0007! - '0011!; claims -----	1, 16, 17, 26, 48-50, 63
X	WO 01/34131 A (WARNER LAMBERT CO ; KLOHS WAYNE DANIEL (US); MERRIMAN RONALD LYNN (US)) 17 May 2001 (2001-05-17)  the whole document -----	1, 14, 15, 18, 19, 26-29, 51-53, 63  -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
---	--

18 August 2004

02/09/2004

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer
--	--------------------

Paul Soto, R

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP2004/007562

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/18393 A (GROVE WILLIAM RICHARD ; WARNER LAMBERT CO (US); KLOHS WAYNE DANIEL (US) 6 April 2000 (2000-04-06)  the whole document -----	1,4,5, 12,13, 26, 30-34, 40-44,63
X	US 6 469 058 B1 (GROVE WILLIAM RICHARD ET AL) 22 October 2002 (2002-10-22)  the whole document -----	1,4,5, 12,13, 26, 30-34, 40-44,63
A	DATABASE WPI Section Ch, Week 200366 Derwent Publications Ltd., London, GB; Class B02, AN 2003-692297 XP002292854 & JP 2003 137866 A (SANKYO CO LTD) 14 May 2003 (2003-05-14) abstract -----	1-63
A	SAITO ET AL: "A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 8, 1999, pages 4592-4597, XP002158228 ISSN: 0027-8424 the whole document -----	1-63
A	WO 02/085400 A (DIMARTINO JORGE ; SUPERGEN INC (US)) 31 October 2002 (2002-10-31) page 7, line 19 - page 9, line 7; claims 8,11,28-33,39,42 page 22, line 3 - page 24, line 4 page 27, lines 1-19 -----	1-63

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/JP2004/007562

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1273296	A	08-01-2003	AT 254915 T CA 2391753 A1 CN 1394601 A CZ 20022216 A3 DE 60200101 D1 DK 1273296 T3 EP 1273296 A2 ES 2208626 T3 HU 0202120 A2 JP 2003055208 A PL 354825 A1 PT 1273296 T SK 9342002 A3 US 2003083366 A1 ZA 200205216 A	15-12-2003 02-01-2003 05-02-2003 14-05-2003 08-01-2004 01-03-2004 08-01-2003 16-06-2004 28-01-2003 26-02-2003 13-01-2003 31-03-2004 01-07-2003 01-05-2003 10-02-2004
US 2003083366	A1	01-05-2003	AT 254915 T CA 2391753 A1 CN 1394601 A CZ 20022216 A3 DE 60200101 D1 DK 1273296 T3 EP 1273296 A2 ES 2208626 T3 HU 0202120 A2 JP 2003055208 A PL 354825 A1 PT 1273296 T SK 9342002 A3 ZA 200205216 A	15-12-2003 02-01-2003 05-02-2003 14-05-2003 08-01-2004 01-03-2004 08-01-2003 16-06-2004 28-01-2003 26-02-2003 13-01-2003 31-03-2004 01-07-2003 10-02-2004
WO 0134131	A	17-05-2001	AU 1583201 A CA 2386876 A1 CN 1387438 T EP 1229916 A2 HU 0203153 A2 JP 2003513912 T NZ 518668 A PL 355170 A1 WO 0134131 A2 US 2003134893 A1 ZA 200202780 A	06-06-2001 17-05-2001 25-12-2002 14-08-2002 28-01-2003 15-04-2003 30-04-2004 05-04-2004 17-05-2001 17-07-2003 09-07-2003
WO 0018393	A	06-04-2000	AT 225655 T AU 762079 B2 AU 5092199 A BG 105470 A BR 9913952 A CA 2342981 A1 CN 1319009 T CZ 20010905 A3 DE 69903458 D1 DE 69903458 T2 DK 1115391 T3 EE 200100187 A EP 1115391 A1 ES 2185378 T3 HR 20010225 A1	15-10-2002 19-06-2003 17-04-2000 31-12-2001 12-06-2001 06-04-2000 24-10-2001 15-08-2001 14-11-2002 10-07-2003 10-02-2003 15-08-2002 18-07-2001 16-04-2003 30-04-2002

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP2004/007562

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0018393	A	HU 0103640 A2		29-06-2002
		ID 30046 A		01-11-2001
		JP 2002525320 T		13-08-2002
		NO 20011493 A		23-05-2001
		NZ 510504 A		26-09-2003
		PL 348673 A1		03-06-2002
		PT 1115391 T		28-02-2003
		SI 1115391 T1		28-02-2003
		SK 3602001 A3		02-07-2002
		TR 200100859 T2		21-08-2001
		WO 0018393 A1		06-04-2000
		US 2003170300 A1		11-09-2003
		US 2003086965 A1		08-05-2003
		US 6469058 B1		22-10-2002
		ZA 200102233 A		18-06-2002
US 6469058	B1 22-10-2002	US 2003170300 A1		11-09-2003
		US 2003086965 A1		08-05-2003
		AT 225655 T		15-10-2002
		AU 762079 B2		19-06-2003
		AU 5092199 A		17-04-2000
		BG 105470 A		31-12-2001
		BR 9913952 A		12-06-2001
		CA 2342981 A1		06-04-2000
		CN 1319009 T		24-10-2001
		CZ 20010905 A3		15-08-2001
		DE 69903458 D1		14-11-2002
		DE 69903458 T2		10-07-2003
		DK 1115391 T3		10-02-2003
		EE 200100187 A		15-08-2002
		EP 1115391 A1		18-07-2001
		ES 2185378 T3		16-04-2003
		HR 20010225 A1		30-04-2002
		HU 0103640 A2		29-06-2002
		ID 30046 A		01-11-2001
		JP 2002525320 T		13-08-2002
		NO 20011493 A		23-05-2001
		NZ 510504 A		26-09-2003
		PL 348673 A1		03-06-2002
		PT 1115391 T		28-02-2003
		SI 1115391 T1		28-02-2003
		SK 3602001 A3		02-07-2002
		TR 200100859 T2		21-08-2001
		WO 0018393 A1		06-04-2000
		ZA 200102233 A		18-06-2002
JP 2003137866	A 14-05-2003	NONE		
WO 02085400	A 31-10-2002	CA 2443560 A1		31-10-2002
		EP 1389127 A1		18-02-2004
		WO 02085400 A1		31-10-2002